Karyopharm Therapeutics (NASDAQ:KPTI) announced its quarterly earnings data on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.88) by $0.09, MarketWatch Earnings reports. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $1.21 million.
Shares of NASDAQ:KPTI traded up $0.05 during trading on Friday, reaching $11.60. 786,589 shares of the company were exchanged, compared to its average volume of 933,786. The firm has a market cap of $721.92 million, a PE ratio of -4.13 and a beta of 3.93. Karyopharm Therapeutics has a 12-month low of $9.00 and a 12-month high of $21.71.
In related news, insider Sharon Shacham sold 12,500 shares of Karyopharm Therapeutics stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $11.65, for a total transaction of $145,625.00. Following the transaction, the insider now directly owns 726,010 shares of the company’s stock, valued at $8,458,016.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock in a transaction that occurred on Tuesday, September 18th. The shares were sold at an average price of $18.26, for a total transaction of $182,600.00. Following the transaction, the chief executive officer now directly owns 522,143 shares in the company, valued at $9,534,331.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 735,788 shares of company stock worth $14,720,105. Corporate insiders own 13.26% of the company’s stock.
A number of brokerages have recently commented on KPTI. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 29th. Robert W. Baird reaffirmed a “buy” rating and set a $25.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 8th. Canaccord Genuity reaffirmed a “buy” rating and set a $27.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, August 7th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research report on Wednesday, July 25th. Finally, BidaskClub lowered shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 25th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $22.90.
COPYRIGHT VIOLATION NOTICE: “Karyopharm Therapeutics (KPTI) Issues Quarterly Earnings Results” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://weekherald.com/2018/11/10/karyopharm-therapeutics-kpti-issues-quarterly-earnings-results.html.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Read More: Diversification
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.